Compare AbbVie Inc (ABBV) vs Comcast Corporation (CMCSA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Comcast Corporation — how do they compare? AbbVie Inc trades at $253.67 (market cap $449.91B), while Comcast Corporation trades at $23.5 (market cap $83.63B). The key difference: AbbVie Inc is far larger — about 5.4× Comcast Corporation's market cap, and Comcast Corporation pays the higher dividend (5.64%). Which is the better fit depends on your goals.
| ABBV | CMCSA | |
|---|---|---|
Market Cap | $449.91B | $83.63B |
Sector | Health | Media |
52-Week High | $261.07 | $34.01 |
52-Week Low | $184.85 | $22.32 |
Enterprise Value | $513.38B | $168.77B |
Dividend Yield | 2.72% | 5.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).
Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.
CMCSA trades at $23.41, down 1.6% over 24 hours, with a bearish technical signal but strong fundamentals including a low P/E of 4.66 and net income margin of 15%. Recent news highlights the planned spin-off of NBCUniversal and Sky's acquisition of ITV's media unit for $2.14 billion, signaling strategic refocusing on broadband infrastructure.
The stock appears undervalued with a consensus price target of $31.07, offering 33% upside, but faces risks from execution of corporate restructuring and pay-TV decline. Positive earnings beats and robust cash flow support a favorable outlook, though investor sentiment is mixed amid spin-off uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Comcast Corporation
Comcast is made up of three parts. The core cable business owns networks capable of providing television, internet access, and phone services to roughly 61 million U.S. homes and businesses, or nearly half of the country. About 56% of the homes in this territory subscribe to at least one Comcast service. Comcast acquired NBCUniversal from General Electric in 2011. NBCU owns several cable networks, including CNBC, MSNBC, and USA, the NBC broadcast network, several local NBC affiliates, Universal Studios, and several theme parks. Sky, acquired in 2018, is the dominant television provider in the U.K. and has invested heavily in exclusive and proprietary content to build this position. The firm is also the largest pay-television provider in Italy and has a presence in Germany and Austria.
Read more on CMCSA →
